David R Nelson, M.D. - Research & Publications

(352) 273-9400

Request an Appointment

Publications

Multisite Investigation of Outcomes With Implementation of Cyp2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Jacc-Cardiovascular Interventions
2018

Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
Hepatology (Baltimore, Md.)
2018

A Comprehensive Assessment of Patient Reported Symptom Burden, Medical Comorbidities, and Functional Well Being in Patients Initiating Direct Acting Antiviral Therapy for Chronic Hepatitis C: Results From a Large US Multi-Center Observational Study
Plos One
2018

Allele-defined genome of the autopolyploid sugarcane Saccharum spontaneum L.
Nature genetics
2018

Evaluating the Efficacy of a Registry Linked to a Consent to Re-Contact Program and Communication Strategies for Recruiting and Enrolling Participants Into Clinical Trials
Contemporary Clinical Trials Communications
2017

Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients With Hepatitis C: Results From the Hcv-Target Study
Hepatology
2017

Safety of the 2D/3D Direct-Acting Antiviral Regimen in Hcv-Induced Child-Pugh a Cirrhosis - a Pooled Analysis
Journal of Hepatology
2017

Effectiveness and Safety of Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 2 Infection: Results of the Real-World, Clinical Practice Hcv-Target Study
Gut
2017

Institutional Profile: University of Florida Health Personalized Medicine Program
Pharmacogenomics
2017

Oral direct-acting agent therapy for hepatitis C infection
Annals of Internal Medicine
2017

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
Gastroenterology
2016

On-Treatment HCV RNa As a Predictor of Sustained Virological Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir
Liver International
2016

Small-Molecule Inhibitor Sorafenib Regulates Immunoreactions By Inducing Survival and Differentiation of Bone Marrow Cells
Innate Immunity
2016

Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C-Infected Patients With Impaired Renal Function
Liver International
2016

HCV Council - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape
Liver International
2016

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
Gastroenterology
2016

Unique Features of a Global Human Ectoparasite Identified Through Sequencing of the Bed Bug Genome
Nature Communications
2016

Resistance analysis of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir
PLOS One
2016

HCV-TARGET Study Group. Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
Gastroenterology
2016

HCVerso 1 and 2: faldaprevir with deleobuvit (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C genotype-1b infection
Clinical and Experimental Gastroenterology
2016

Hcverso1 and 2: Faldaprevir With Deleobuvir (Bi 207127) and Ribavirin for Treatment-Naive Patients With Chronic Hepatitis C Virus Genotype-1B Infection
Clinical and Experimental Gastroenterology
2016

On-treatment HCV RNA as a predictor of sustained virologic response in HCV genotype 3-infected patients treated with Daclatasvir and Sofosbuvir
Liver International
2016

Interferon-Free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real-World Experience From the Hepatitis C Therapeutic Registry and Research Network
Liver Transplantation
2016

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
Gut
2016

Grazoprevir Plus Elbasvir in Treatment-Naive and Treatment-Experienced Patients With Hepatitis C Virus Genotype 1 Infection and Stage 4-5 Chronic Kidney Disease (the C-Surfer Study): a Combination Phase 3 Study
Lancet
2015

Designing a Ctsa-Based Social Network Intervention to Foster Cross-Disciplinary Team Science
Cts-Clinical and Translational Science
2015

Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated By Race Or Ethnicity
Journal of Clinical Gastroenterology
2015

Virological Outcomes and Treatment Algorithms Utilisation in Observational Study of Patients With Chronic Hepatitis C Treated With Boceprevir Or Telaprevir
Alimentary Pharmacology & Therapeutics
2015

Accuracy of Fibroscan, Compared With Histology, in Analysis of Liver Fibrosis in Patients With Hepatitis B Or C: a United States Multicenter Study
Clinical Gastroenterology and Hepatology
2015

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: Ally-3 Phase III Study
Hepatology
2015

Safety Profile of Boceprevir and Telaprevir in Chronic Hepatitis C: Real World Experience From Hcv-Target
Journal of Hepatology
2015

Optimal Interferon-Free Therapy in Treatment-Experienced Chronic Hepatitis C Patients
Liver International
2015

Open-label study to evaluate the safety and tolerability of Telaprevir in combination with Sofosbuvir in naïve subjects with HCV genotype 1
Journal of Gastroenterology and Hepatology
2015

Development of sofosbuvir for the treatment of hepatitis C virus infection
Annals of the New York Academy of Sciences
2015

Clinical Trial design for alpha-a antitrypsin deficiency: a model for rare diseases
Copd-Journal of Chronic Obstructive Pulmonary Disease
2015

All-Oral 12-Week Combination Treatment With Daclatasvir (Dcv) and Sofosbuvir (Sof) in Patients Infected With Hcv Genotype (Gt) 3: Ally-3 Phase 3 Study
Hepatology
2014

Integrated Metabolomic Profiling of Hepatocellular Carcinoma in Hepatitis C Cirrhosis Through Gc/Ms and Uplc/Ms-Ms
Liver International
2014

Effects of Sofosbuvir-Based Treatment, With and Without Interferon, On Outcome and Productivity of Patients With Chronic Hepatitis C
Clinical Gastroenterology and Hepatology
2014

Direct-Acting Antiviral Agents and the Path To Interferon Independence
Clinical Gastroenterology and Hepatology
2014

Minimal Impact of Sofosbuvir and Ribavirin On Health Related Quality of Life in Chronic Hepatitis C (Ch-C)
Journal of Hepatology
2014

Ledipasvir and Sofosbuvir for Previously Treated Hcv Genotype 1 Infection
New England Journal of Medicine
2014

Daclatasvir Plus Sofosbuvir for Hcv Infection Reply
New England Journal of Medicine
2014

Clinical Pharmacogenetics Implementation: Approaches, Successes, and Challenges
American Journal of Medical Genetics. Part C: Seminars in Medical Genetics
2014

Genome-Wide Association Study To Characterize Serum Bilirubin Elevations in Patients With Hcv Treated With Gs-9256, An Hcv Ns3 Serine Protease Inhibitor
Antiviral Therapy
2014

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1
New England Journal of Medicine
2014

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
New England Journal of Medicine
2014

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
New England Journal of Medicine
2014

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
New England Journal of Medicine
2014

VX-222, a non-nucleoside NS5B polymerase inhibitor in telaprevir-based regimens for genotype 1 hepatitis C virus infection
European Journal of Gastroenterology and Hepatology
2014

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens
Clinical Pharmacology & Therapeutics
2014

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
Hepatology
2014

Effects of Ribavirin Dose Reduction Vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-a Randomized Trial
Gastroenterology
2013

Sofosbuvir Plus Ribavirin With Or Without Peginterferon Is Well-Tolerated and Associated With High Svr Rates: Integrated Results From 4 Phase 3 Trials in Hcv Genotype 1-6
The American Journal of Gastroenterology
2013

Successful Treatment With Sofosbuvir (Sof) Regimen Improves Patient-Reported Outcomes (Pros) in Patients With Chronic Hepatitis C (Ch-C)
The American Journal of Gastroenterology
2013

Safety and Efficacy of Interferon-Free Regimens of Abt-450/R, Abt-267, Abt-333 +/- Ribavirin in Patients With Chronic Hcv Gti Infection: Results From the Aviator Study
The American Journal of Gastroenterology
2013

Sofosbuvir and Ribavirin Achieves High Svr in Patients With Genotype 2 Or 3 Hcv Infection Who Are Without Treatment Options
Journal of Gastroenterology and Hepatology
2013

Deep Sequencing Analysis of Hcv Ns3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients
PLOS One
2013

Neutrophil-Lymphocyte Ratio Predicts Overall and Recurrence-Free Survival After Liver Transplantation for Hepatocellular Carcinoma
Hepatology Research
2013

Sofosbuvir With Pegylated Interferon Alfa-2a and Ribavirin for Treatment-Naive Patients With Hepatitis C Genotype-1 Infection (Atomic): An Open-Label, Randomised, Multicentre Phase 2 Trial
Lancet
2013

Composite Fatty Acid Ether Amides Suppress Growth of Liver Cancer Cells in Vitro and in An in Vivo Allograft Mouse Model
Cellular Oncology
2013

University of Florida and Shands Hospital Personalized Medicine Program: Clinical Implementation of Pharmacogenetics.
Pharmacogenomics
2013

Sofosbuvir in Combination With Peginterferon Alfa-2a and Ribavirin for Non-Cirrhotic, Treatment-Naive Patients With Genotypes 1, 2, and 3 Hepatitis C Infection: a Randomised, Double-Blind, Phase 2 Trial
Lancet Infectious Diseases
2013

Sofosbuvir for Hepatitis C Genotype 2 Or 3 in Patients Without Treatment Options
New England Journal of Medicine
2013

Argininosuccinate Synthase as a Novel Biomarker for Inflammatory Conditions
Biomarkers
2013

Sustained Virologic Response With Daclatasvir Plus Sofosbuvir +/- Ribavirin (Rbv) in Chronic Hcv Genotype (Gt) 1-Infected Patients Who Previously Failed Telaprevir (Tvr) Or Boceprevir (Boc)
Journal of Hepatology
2013

Treatment With Sofosbuvir Plus Ribavirin for 12 Weeks Achieves Svr12 of 78\% in Gt2/3 Interferon-Ineligible, -Intolerant, Or -Unwilling Patients: Results of the Phase 3 Positron Trial
Journal of Hepatology
2013

Immune Modulation of Effector Cd4+ and Regulatory T Cell Function By Sorafenib in Patients With Hepatocellular Carcinoma
Cancer Immunology Immunotherapy
2013

Sofosbuvir (Gs-7977) Plus Peginterferon/Ribavirin in Treatment-Naive Patients With Hcv Genotype 1: a Randomized, 28-Day, Dose-Ranging Trial
Journal of Hepatology
2013

Hcv-Target: a Longitudinal, Observational Study of North American Patients With Chronic Hepatitis C (Hcv) Treated With Boceprevir Or Telaprevir
Journal of Hepatology
2013

Once Daily Sofosbuvir Plus Ribavirin for 12 and 24 Weeks in Treatment-Naive Patients With Hcv Infection: the Quantum Study
Journal of Hepatology
2013

High Svr Rates (Svr4) for 12-Week Total Telaprevir Combination Therapy in Il28B Cc Treatment-Naives and Prior Relapsers With G1 Chronic Hepatitis C: Concise Interim Analysis
Journal of Hepatology
2013

All Oral Therapy With Sofosbuvir Plus Ribavirin for 12 Or 16 Weeks in Treatment Experienced Gt2/3 Hcv-Infected Patients: Results of the Phase 3 Fusion Trial
Journal of Hepatology
2013

Treatment Outcomes and Prognostic Factors of Intrahepatic Cholangiocarcinoma
Oncology Reports
2013

New Therapeutic Strategies in Hcv: Second-Generation Protease Inhibitors
Liver International
2013

Opa1 Downregulation Is Involved in Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Laboratory Investigation
2013

The Anti-Viral Effect of Sorafenib in Hepatitis C-Related Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics
2013

Institutional Profile: University of Florida & Shands Hospital Personalized Medicine Program: Clinical Implementation of Pharmacogenetics
Pharmacogenomics
2013

Efficacious versus effective: what’s in an adjective?
Simulation in Healthcare-Journal of the Society for Simulation in Healthcare
2013

Patient-reported immunosuppression nonadherence 6 to 24 months after liver transplant: association with pretransplant psychosocial factors and perceptions of health status change
Progress in Transplantation
2013

Cc Genotype Donors for the Interleukin-28B Single Nucleotide Polymorphism Are Associated With Better Outcomes in Hepatitis C After Liver Transplant
Liver International
2013

High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (Ns5a Inhibitor) Plus Sofosbuvir (Nucleotide Ns5B Inhibitor), With Or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With Hcv Genotype 1, 2, Or 3
Hepatology
2012

A 12-Week Interferon-Free Treatment Regimen With Abt-450/R, Abt-267, Abt-333 and Ribavirin Achieves Svr12 Rates (Observed Data) of 99\% in Treatment-Naive Patients and 93\% in Prior Null Responders With Hcv Genotype1 Infection
Hepatology
2012

Genome-Wide Association Study To Characterize Potential Determinants of Bilirubin Elevations in Hcv Patients Receiving the Hcv Ns3 Serine Protease Inhibitor Gs-9256
Higher Education Policy
2012

Serum Levels of Soluble Cd25 as a Marker for Hepatocellular Carcinoma
Oncology Letters
2012

Vx-222, Telaprevir and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C: Results of the Zenith Study Interferon-Free Regimen
Higher Education Policy
2012

Incidentally Discovered Hcc (Ihcc) in Explant Liver- Clinical and Histopathologic Features and Outcome
Higher Education Policy
2012

The Safety of Telaprevir in the Absence of Interferon And/Or Ribavirin: Analysis of On-Treatment Data From the Zenith Trial
Higher Education Policy
2012

Once Daily Sofosbuvir (Gs-7977) Plus Peg/Rbv: High Early Response Rates Are Maintained During Post-Treatment Follow-Up in Treatment-Naive Patients With Hcv Genotype 1, 4, and 6 Infection in the Atomic Study
Higher Education Policy
2012

The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy
2012

Boceprevir (Boc) Combined With Peginterferon Alfa-2B/Ribavirin (P/Rbv) in Treatment-Naive Chronic Hcv Genotype 1 Patients With Compensated Cirrhosis: Sustained Virologic Response (Svr) and Safety Subanalyses From the Anemia Management Study
Higher Education Policy
2012

Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma On Long-Term Outcomes After Liver Transplantation
American Journal of Clinical Oncology-Cancer Clinical Trials
2012

Levels of Alanine Aminotransferase Confound Use of Transient Elastography To Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection
Clinical Gastroenterology and Hepatology
2012

Diagnosis and Management of Patients With Alpha(1)-Antitrypsin (A1At) Deficiency
Clinical Gastroenterology and Hepatology
2012

Atomic: 97\% Rvr for Psi-7977+Peg/Rbv X 12 Week Regimen in Hcv Gt1: An End To Response-Guided Therapy?
Journal of Hepatology
2012

Potent Viral Suppression With All-Oral Combination of Daclatasvir (Ns5a Inhibitor) and Gs-7977 (Ns5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic Hcv Gt1, 2, Or 3
Journal of Hepatology
2012

Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS)
Cts-Clinical and Translational Science
2012

Peginterferon Lambda-1a (Lambda) Compared To Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With Hcv Genotypes (G) 2 Or 3: First Svr24 Results From Emerge Phase Iib
Journal of Hepatology
2012

Psi-7977 Proton and Electron: 100\% Concordance of Svr4 With Svr24 in Hcv Gt1, Gt2, and Gt3
Journal of Hepatology
2012

High Svr12 With 16 Weeks of Tegobuvir and Gs-9256 With Peginterferon-Alfa 2a and Ribavirin in Treatment-Naive Genotype 1 Hcv Patients
Journal of Hepatology
2012

Psi-7977 400 Mg Qd Safety and Tolerability in the First 450 Patients Treated for 12 Weeks
Journal of Hepatology
2012

An Update On Treatment of Hepatitis C Virus Genotype 1 Infection and Viral Load Assessments Reply
Higher Education Policy
2012

The Role of Ribavirin in Direct Acting Antiviral Drug Regimens for Chronic Hepatitis C
Liver International
2012

Balapiravir Plus Peginterferon Alfa-2a (40Kd)/Ribavirin in a Randomized Trial of Hepatitis C Genotype 1 Patients
Annals of Hematology
2012

Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008
BMC Research Notes
2012

Viral Clearance Is Associated With Improved Insulin Resistance in Genotype 1 Chronic Hepatitis C But Not Genotype 2/3
Gut
2012

Hepatitis C virus: a critical appraisal of new approaches to therapy
Hepatitis Research and Treatment
2012

Liver test results do not identify liver disease in adults with alpha-1 antitrypsin deficiency
Clinical Gastroenterology and Hepatology
2012

University of Florida Clinical and Translational Science Institute: Transformation and Translation in Personalized Medicine
Cts-Clinical and Translational Science
2011

Once-Daily Psi-7977 Plus Peg/Rbv in Treatment-Naive Patients With Hcv Gt1: Robust End of Treatment Response Rates Are Sustained Post-Treatment
Higher Education Policy
2011

Identification of the Ifitm3 Gene as An Inhibitor of Hepatitis C Viral Translation in a Stable Stat1 Cell Line
Journal of Viral Hepatitis
2011

Klatskin Tumor- Clinical Outcome and Prognostic Factors
Higher Education Policy
2011

Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated With a Telaprevir-Based Regimen Regardless of Liver Fibrosis Stage
Higher Education Policy
2011

Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma
Higher Education Policy
2011

Vx-222/Telaprevir in Combination With Peginterferon-Alfa-2a and Ribavirin in Treatment-Naive Genotype 1 Hcv Patients Treated for 12 Weeks: Zenith Study, Svr12 Interim Analysis
Higher Education Policy
2011

Sustained Virologic Response (Svr) in American Naive Mono-Infected Chronic Hepatitis C (Chc) Patients (Pts) Treated With Peginterferon Alfa (Pegifn Alpha) Plus Ribavirin (Rbv): Final Analysis of the Large, Multinational Real-World Prophesys Database
Higher Education Policy
2011

Expression of An Irf-3 Fusion Protein and Mouse Estrogen Receptor, Inhibits Hepatitis C Viral Replication in Rig-I-Deficient Huh 7.5 Cells
Virology Journal
2011

Is Model for End-Stage Liver Disease Score Associated With Quality of Life After Liver Transplantation?
Progress in Transplantation
2011

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
New England Journal of Medicine
2011

Steatosis Is An Independent Predictor of Relapse Following Rapid Virologic Response in Patients With Hcv Genotype 3
Clinical Gastroenterology and Hepatology
2011

Racial differences in hepatitis C treatment eligibility Hepatology
Hepatology
2011

The Combination of Sorafenib With Transarterial Chemoembolisation for Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics
2011

Characterization of Hcv Interactions With Toll-Like Receptors and Rig-I in Liver Cells
PLOS One
2011

Phoenix: a Randomized Controlled Trial of Peginterferon Alfa-2a Plus Ribavirin as a Prophylactic Treatment After Liver Transplantation for Hepatitis C Virus
Liver Transplantation
2011

Kinase Inhibitor Sorafenib Modulates Immunosuppressive Cell Populations in a Murine Liver Cancer Model
Modern Pathology
2011

A Sustained Viral Response Dramatically Improves Survival in Patients With Hepatitis C Infection After Liver Transplant
Journal of Hepatology
2011

Once Daily Psi-7977 Plus Peg-Ifn/Rbv in Hcv Gt1: 98\% Rapid Virologic Response, Complete Early Virologic Response: the Proton Study
Journal of Hepatology
2011

Once Daily Psi-7977 Plus Pegifn/Rbv in a Phase 2B Trial: Rapid Virologic Suppression in Treatment-Naive Patients With Hcv Gt2/Gt3
Journal of Hepatology
2011

Alt Abnormalities in Adults With Alpha-1 Antitrypsin Deficiency
Journal of Hepatology
2011

24-Week Treatment With Cts-1027 in Combination With Ribavirin Reduces Hcv-Rna in Treatment Naive Genotype-1 Patients
Journal of Hepatology
2011

Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-Naive Patients Regardless of Race Or Ethnicity
Journal of Hepatology
2011

Pegylated Interferon-Lambda (Pegifn-Lambda) Shows Superior Viral Response With Improved Safety and Tolerability Versus Pegifn Alpha-2a in Hcv Patients (G1/2/3/4): Emerge Phase Iib Through Week 12
Journal of Hepatology
2011

Vx-222 With Tvr Alone Or in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C: Zenith Study Interim Results
Journal of Hepatology
2011

Reactive Oxygen Species Is Essential for Cycloheximide To Sensitize Lexatumumab-Induced Apoptosis in Hepatocellular Carcinoma Cells
PLOS One
2011

An Update Of Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline By the American Association for the Study of Liver Diseases
Hepatology
2011

Different Radiosensitivity of Cd4(+)Cd25(+) Regulatory T Cells and Effector T Cells To Low Dose Gamma Irradiation in Vitro
International Journal of Radiation Biology
2011

Low Prevalence of Hbv Dna in the Liver Allograft From Anti-Hbc-Positive Donors: a Single-Center Experience
Clinical Transplantation
2011

Pilot Study: Fenofibrate for Patients With Primary Biliary Cirrhosis and An Incomplete Response To Ursodeoxycholic Acid
Alimentary Pharmacology & Therapeutics
2011

Boceprevir for untreated chronic HCV genotype 1 infection
New England Journal of Medicine
2011

The Role of Triple Therapy With Protease Inhibitors in Hepatitis C Virus Genotype 1 Naive Patients
Liver International
2011

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Hepatology
2011

Hepatitis C Virus Modulates Human Monocyte-Derived Dendritic Cells
Journal of Viral Hepatitis
2010

Transfusion Has No Effect On Recurrence in Hepatitis C After Liver Transplantation
Acta Anaesthesiologica Scandinavica
2010

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
Gastroenterology
2010

Hepatitis B Reactivation and Rituximab in the Oncology Practice
Oncologist
2010

Influence of Serum and Soluble Cd25 (Scd25) On Regulatory and Effector T-Cell Function in Hepatocellular Carcinoma
Scandinavian Journal of Immunology
2010

The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant
Higher Education Policy
2010

Genotype-Specific Predictors of Early Viral Clearance Following Treatment With Peginterferon Alfa-2a (40Kd) (Pegifn Alpha-2A) Plus Ribavirin (Rbv): Multiple Logistic Regression Analysis From the Large Multinational Prophesys Cohorts
Higher Education Policy
2010

Clinical Synergy of An Anti-Hcv Nucleoside Analog With Soc: Viral Kinetics of Psi-7977 With Society
Higher Education Policy
2010

Predictors of Relapse in Genotype 3 Infected Chronic Hcv Patients Who Achieve Rapid Virologic Response
Higher Education Policy
2010

Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Gastroenterology
2010

The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation
Higher Education Policy
2010

Telaprevir in Combination With Peginterferon Alfa2a and Ribavirin for 24 Or 48 Weeks in Treatment-Naive Genotype 1 Hcv Patients Who Achieved An Extended Rapid Viral Response: Final Results of Phase 3 Illuminate Study
Higher Education Policy
2010

Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1
Gastroenterology
2010

Safety and Virologic Response Rates in Patients With History of Injection Drug Use (Idu): Pooled Analysis of Data From Four Randomized Phase III Studies of Peginterferon Alfa-2a (40Kd) Plus Ribavirin (Rbv)
Higher Education Policy
2010

Fatigue and Sleep Quality Before and After Liver Transplantation
Progress in Transplantation
2010

Identifying Hepatitis C Virus Genotype 2/3 Patients Who Can Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin
Hepatology
2010

New Therapies in the Management of Hepatitis C Virus
Current Opinion in Gastroenterology
2010

Review Article: the Management of Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics
2010

Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).
Digestive Diseases and Sciences
2010

Baseline Characteristics Associated With Prescription of Ribavirin > 800 Mg/Day Among G2/3 Patients Prescribed Peginterferon Alfa-2a (40Kd) From Real-World Patient Cohorts: Interim Results From Prophesys
Journal of Hepatology
2010

Phase Iib Study of Balapiravir (Rg1626; Nucleoside Analogue Inhibitor of Hcv Polymerase) Plus Peginterferon Alfa-2a (40Kd) and Ribavirin for Chc Genotype 1: Final Results
Journal of Hepatology
2010

Transfusion has no effect on recurrence in hepatitis C after liver transplantation.
Acta Anaesthesiologica Scandinavica
2010

Evaluating Virologic Response Within 2-4 Weeks Has High Positive/Negative Predictive Values for Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C During Treatment
Journal of Hepatology
2010

The Use of Cyclosporine for Recurrent Hepatitis C After Liver Transplant: a Randomized Pilot Study
Digestive Diseases and Sciences
2010

Longitudinal Prospective Comparison of Fibrosure and Transient Elastography in Relation To Virologic Response: a Substudy of the Phase 3 Albinterferon Alfa-2B Trials
Journal of Hepatology
2010

Telaprevir for previously treated chronic HCV infection
New England Journal of Medicine
2010

Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B Or Peginterferon Alfa-2a
Journal of Hepatology
2010

Identifying HCV genotype 2/3 patients who can receive a 16 week abbreviated course of peginterferon alfa-2a plus ribavirin
Hepatology
2010

Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.
Scandinavian Journal of Immunology
2010

Marked Spirometry Decline in Patients With Chronic Hepatitis C During Treatment With Albinterferon Alfa-2B Is Similar To Peginterferon Alfa-2a
Journal of Hepatology
2010

Influence of serum and soluble CD25 on regulatory and effector T-cell function in hepatocellular carcinoma
Scandinavian Journal of Immunology
2010

Characterization of anti-HCV antibodies in IL-10-treated patients
Viral Immunology
2010

Hepatitis C Drug Development At a Crossroads
Higher Education Policy
2009

Insulin Resistance and Hepatic Steatosis Are Both Independently Associated With Advanced Hepatic Fibrosis in Chronic Hepatitis C Infection: Analysis of the Achieve 1 and Achieve 2/3 Cohorts
Higher Education Policy
2009

Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 Or 3
Higher Education Policy
2009

Identifying Hcv Genotype 2/3 Patients Who Could Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin
Higher Education Policy
2009

Longitudinal Prospective Comparison of Fibrosure and Fibroscan in Relation To Virologic Response in a Phase III Study of Albinterferon Alfa-2B and Ribavirin in Treatment Naive Chc Patients
Higher Education Policy
2009

A Randomized Controlled Trial of the Efficacy, Tolerability, and Safety of Prophylactic Treatment With Peginterferon Alfa-2a Plus Ribavirin After Orthotopic Liver Transplantation (Olt) for Hepatitis C: the Phoenix Study
Higher Education Policy
2009

Sustained Virologic Response 15 Independently Associated With Improvement in Insulin Resistance in Genotype 1, But Not Genotype 2/3, Chronic Hcv Patients
Higher Education Policy
2009

Anti-Hepatitis C Viral Activities By Inducible Stat1 Activation
Higher Education Policy
2009

Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis
Higher Education Policy
2009

Similar Rates of Interstitial Findings On Chest X-Ray in Hcv Patients Treated With Albinterferon Alfa-2B Or Peginterferon Alfa-2a
Higher Education Policy
2009

Hepatitis B Viral Dna Seldom Present in the Transplant Liver From Anti-Hbc-Positive Donors
Higher Education Policy
2009

The Natural History of Hepatitis C Cirrhosis After Liver Transplantation
Liver Transplantation
2009

A Randomized Controlled Trial of Thymalfasin Plus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
Hepatology International
2009

A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C: Viser1 Results
Higher Education Policy
2009

Novel Interferons for Treatment of Hepatitis C Virus
Clinics in Liver Disease
2009

Intraoperative Red Cell and Platelet Transfusion Have No Effect On Survival Or Histologic Disease Recurrence in Hepatitis C Patients After Liver Transplantation
Liver Transplantation
2009

Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells.
Cell Biology International
2009

Changes in B-Lymphocyte Stimulator Protein Levels During Treatment With Albinterferon Alfa-2B in Patients With Chronic Hepatitis C Who Have Failed Previous Interferon Therapy
Hepatology Research
2009

Gamma Irradiation Alters the Phenotype and Function of Cd4(+)Cd25(+) Regulatory T Cells
Cell Biology International
2009

Hepatitis C Virus: a Critical Appraisal of Approaches To Therapy
Clinical Gastroenterology and Hepatology
2009

Safety and Antiviral Activity of Albinterferon Alfa-2B in Prior Interferon Nonresponders With Chronic Hepatitis C
Clinical Gastroenterology and Hepatology
2009

Ribavirin: Current Role in the Optimal Clinical Management of Chronic Hepatitis C
Journal of Hepatology
2009

Using An Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients
Liver Transplantation
2009

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
New England Journal of Medicine
2009

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Clinical Gastroenterology and Hepatology
2009

Improving the Standard of Care for HCV Management: Available and Emerging Strategies for Optimal Patient Outcomes
PeerView
2009

PROVE 1: Telapravir with peginterferon and ribavirin for chronic HCV genotype 1 infection
New England Journal of Medicine
2009

Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Interferon-Alfa Treatment Naive Patients With Genotype 2 Or 3 Chronic Hepatitis C
Journal of Hepatology
2009

Efficacy and Safety of the Cyclophilin Inhibitor Debio 025 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Previously Null-Responder Genotype 1 Hcv Patients
Journal of Hepatology
2009

The natural history of hepatitis C cirrhosis after liver transplantation.
Liver Transplantation
2009

Gamma radiation alters the phenotype and function of CD4+CD25+ regulatory cells
Cell Biology International
2009

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
New England Journal of Medicine
2009

Factors Predicting Survival After Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years' Experience From a Single Tertiary Medical Center
Journal of Vascular and Interventional Radiology
2008

Using Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients
Higher Education Policy
2008

High Relapse Rate Seen At Week 72 for Patients Treated With R1626 Combination Therapy
Higher Education Policy
2008

Potent Antiviral Response To the Hcv Nucleoside Polymerase Inhibitor R7128 for 28 Days With Peg-Ifn and Ribavirin: Subanalysis By Race/Ethnicity, Weight and Hcv Genotype
Higher Education Policy
2008

Improved Outcomes in Patients With Hepatitis C With Difficult-To-Treat Characteristics: Randomized Study of Higher Doses of Peginterferon Alpha-2a and Ribavirin
Higher Education Policy
2008

Is Sonographic Surveillance of Polytetrafluoroethylene-Covered Transjugular Intrahepatic Portosystemic Shunts (Tips) Necessary? a Single Centre Experience Comparing Both Types of Stents
Clinical Radiology
2008

Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 in Hcv Genotype 2 and 3 Prior Non-Responders: Interim Results of R7128 1500Mg Bid With Peg-Ifn and Ribavirin for 28 Days
Higher Education Policy
2008

R1626 Plus Peginterferon Alfa-2a Provides Potent Suppression of Hepatitis C Virus Rna and Significant Antiviral Synergy in Combination With Ribavirin
Higher Education Policy
2008

A Cross-Sectional Study of Fatigue Before and After Liver Transplantation
American Journal of Transplantation
2008

Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients With Hepatitis C
American Journal of Transplantation
2008

Management of viral hepatitis in hematologic malignancies.
Blood Reviews
2008

Meld and Prediction of Quality of Life One-Year After Liver Transplantation.
American Journal of Transplantation
2008

Correlation of Fibrospect Ii With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C
Clinical Gastroenterology and Hepatology
2008

Ribavirin Considerations in Treatment Optimization
Antiviral Therapy
2008

Potent Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 With Peg-Ifn and Ribavirin: Interim Results of R7128 500Mg Bid for 28 Days
Journal of Hepatology
2008

The Natural History of Hcv-Related Cirrhosis After Liver Transplantation
Journal of Hepatology
2008

Dynamic Evolution of Therapy for Chronic Hepatitis C: How Will Novel Agents Be Incorporated Into the Standard of Care?
Antiviral Therapy
2008

Cyclosporine Helps To Achieve a Higher Svr in Patients Receiving Peg-Interferon/Ribavirin for Recurrent Hepatitis C After Liver Transplantation: Final Analysis of a Randomized-Controlled Study
Journal of Hepatology
2008

Hepatocellular Carcinoma Is Associated With An Impaired Cd4 T Cell Immune Response
Journal of Hepatology
2008

High End-Of-Treatment Response (84\%) After 4 Weeks of R1626, Peginterferon Alfa-2a (40Kd) and Ribavirin Followed By a Further 44 Weeks of Peginterferon Alfa-2a and Ribavirin
Journal of Hepatology
2008

Antiviral Activity and Changes in B-Lymphocyte Stimulator Protein Levels During Treatment With Albinterferon Alfa-2B/Ribavirin in Prior Interferon-Therapy Nonresponders
Journal of Hepatology
2008

Factors prediciting survival after transjugular intrahepatic portosystemic shunt creation: 15 years experience from a single tertiary medical center
Journal of Vascular and Interventional Radiology
2008

Is sonographic surveillance of polytetrafluorethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary? A single center experience comparing both types of stents
Clinical Radiology
2008

Correlation of Fibrospect II with histological and morphometric evaluation of liver fibrosis in chronic hepatitis C
Clinical Gastroenterology and Hepatology
2008

Improved outcomes in patients with hepatitis C with difficult to treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
Hepatology
2008

The Failing Liver
Gastroenterology
2007

16 vs 24 weeks of peginterferon alfa-2a plus ribavirin for patients with HCV genotypes 2 or 3 infection
New England Journal of Medicine
2007

Virological response and safety outcomes in therapy naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study
Journal of Hepatology
2007

Current and future hepatitis C therapies.
Archives of Medical Research
2007

Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis.
Clinical Gastroenterology and Hepatology
2007

Final Results of A Double-Blind, Placebo-Controlled Trial of the Antifibrotic Efficacy of Interferon-gamma 1b in Chronic Hepatitis C Patients with Advanced Fibrosis or Cirrhosis
Hepatology
2007

Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system
Gastroenterology
2007

Anti-HCV activity of albinterferon alfa-2b in cell culture
Hepatology Research
2007

Is early recurrence of hepatitis C associated with biliary anastamotic stricture after liver transplantation?
Transplantation
2007

Virological response and safety outcomes in therapy naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study
Hepatology
2007

Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells
Laboratory Investigation
2007

New inhibitors of the HCV life cycle
Hot Topics in Viral Hepatitis
2007

New Inhibitors of the HCV Life Cycle
Hot Topics in Viral Hepatitis
2007

Viral hepatitis: manifestations and management strategy
Hematology
2006

Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis.
Liver Transplantation
2006

Global transcriptional effects of PEG-IFN-alfa on peripheral blood cells obtained from patients with chronic hepatitis C
Hepatology Research
2006

Clinical and financial impact of obesity on the outcome of liver transplantation.
Transplantation proceedings
2006

Impact of implementation of the MELD Scoring system on the prevalence and incidence of chronic liver disease following liver transplantation
Liver Transplantation
2006

Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation
Digestive Diseases and Sciences
2006

Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease
Clinical Gastroenterology and Hepatology
2006

Combined hepatic resection and radiofrequency ablation for multiple hepatic adenomas.
Journal of Gastroenterology and Hepatology
2006

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
Liver Transplantation
2006

Longterm Care of the Liver Transplant Recipient
Therapy of Digestive Disorders
2006

Cyclosporine Suppresses Hepatitis C In Vitro and Increases the Chance of a Sustained Virological Response After Liver Transplantation
Liver Transplantation
2006

A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
Antiviral Therapy
2006

Pathogenesis of recurrent hepatitis C after liver transplantation
Current Hepatitis Reports
2005

A brief psychological intervention to improve adherence following transplantation
Annals of Transplantation
2005

Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation
Hepatology
2005

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
Virology Journal
2005

Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C IFN-alpha resistance
Journal of Interferon & Cytokine Research
2005

Liver retransplantation: a single-center outcome and financial analysis.
Transplantation proceedings
2005

Early Hepatic Stellate Cell Activation Is Associate With Advanced Fibrosis after Liver Transplantation In Recipients With Hepatitis C
Liver Transplantation
2005

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
Liver Transplantation
2005

Short recovery time after percutaneous liver biopsy: should we change our current practices?
Clinical Gastroenterology and Hepatology
2005

Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation
Hepatology
2005

Short-Recovery Time After Percutaneous Liver Biopsy: Should We Change Our Current Practices?
Clinical Gastroenterology and Hepatology
2005

Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease
Hepatology
2004

One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
Liver Transplantation
2004

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Liver Transplantation
2004

Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis
Laboratory Investigation
2004

An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Hepatology
2004

Mutant Beta-Catenin promotes hepatocyte proliferation and inhibits TNF-induced apoptosis
Lab Investigations
2004

Keratin 8 and 18 hyperphosphorylation is a marker of human liver disease progression
Hepatology
2004

Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research.
Liver Transplantation
2004

Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection.
Liver Transplantation
2003

CD8+ T cell interaction with the HCV replicon cells: evidence for both cytokine and cell-mediated antiviral activity
Hepatology
2003

Gene expression associated with IFN alpha antiviral activity in a HCV replicon cell line
Hepatology
2003

Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.
Higher Education Policy
2003

Immunopathogenesis of Viral Hepatitis
Hepatitis
2003

Future Drug Development
Experts Perspectives on Contemporary Clinical Issues in Hepatitis C
2002

Liver transplantation for hepatocellular carcinoma.
Minerva chirurgica
2002

Combination Of Interferon Alfa-2b and Ribavirin in liver transplant recipients with histologic recurrent hepatitis C
Liver Transplantation
2002

Interleukin 10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription
Nitric Oxide-Biology and Chemistry
2002

The immunopathogenesis of hepatitis C virus infection.
Clinics in Liver Disease
2001

Combined hepatic resection and radiofrequency ablation for hepatic adenomatosis
HPB Surgery
2001

Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Liver Transplantation
2001

Interleukin-12 production in chronic hepatitis C infection
Journal of Hepatology
2000

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Gastroenterology
2000

The utility of noninvasive serologic markers in the managment of early allograft rejection in liver transplantation recipients
Transplantation
1999

Future options for the management of hepatitis C
Liver Disease
1999

Intrahepatic HCV-specific CTL activity and response to interferon therapy in chronic HCV
Hepatology
1998

Determination of HCV-Specific Bulk CD8(+) Activity in Liver
Methods in Molecular Medicine
1998

Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection
Clinics in Liver Disease
1997

Serum interleukin 4 and interleukin 10 in patients with chronic hepatitis C virus infection
Journal of Hepatology
1997

Treatment of chronic hepatitis C
Comprehensive Therapy
1997

The role of hepatits C virus-specific cytotoxic T lymphocytes in chronic hepatits C
Journal of Immunology
1997

Elevated serum interleukin 4 and interleukin 10 in patients with chronic hepatitis C virus infection
Journal of Hepatology
1997

Transforming growth factor- 1 in chronic hepatitis C
Journal of Viral Hepatitis
1997

Anti-GOR in chronic HCV patients with membranoproliferative glomerulonephritis
Journal of Hepatology
1996

Host immune response in hepatitis C virus infection
Viral Hepatitis Reviews
1996

Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy
Journal of Viral Hepatitis
1995

Alpha-Glutathione S-transferase as a marker of hepatocellular damage in chronic hepatitis C virus infection
American Journal of Clinical Pathology
1995

Research Interests

Dr. Nelson's research primarily focuses on the immunopathogenesis and treatment of chronic hepatitis C and hepatocellular carcinoma. He oversees more than 15 active clinical trials and serves as principal investigator on basic science, clinical research and training grants in gastroenterology and hepatobiliary diseases. Dr. Nelson has an impressive record of academic achievement with more than $30 million in research funding and more than 200 publications.

Active Research Studies